Sanofi delivers 2018 business EPS growth of 5.1% at CER
06 Febrero 2019 - 11:30PM
JCN Newswire (English)
PARIS, FRANCE, Feb 7, 2019 - (ACN Newswire) - Sanofi announced the
2018 fourth-quarter and full-year results.
Fourth-quarter sales growth driven by Specialty Care and
Vaccines
- Net sales were EUR8,997 million, an increase of 3.5% on a
reported basis, 3.9% at CER and 2.6% at CER/CS.
- Sanofi Genzyme sales were up 37.4% (16.1% at CER/CS), led by
Immunology and Rare Blood Disorder franchises.
- Vaccines sales increased 9.7%, driven by successful influenza
differentiation strategy and Menactra(R).
- CHC sales increased 1.9%, supported by Emerging Markets.
- DCV GBU sales were down 11.3%; Global Diabetes franchise sales
declined 10.5% in line with 2015-2018 guidance.
- Emerging Markets sales were up 6.0%, reflecting strong
performance in Asia.
Full-Year 2018 sales growth from new products and Emerging markets
more than offset impact of U.S. LoEs
- Net sales in 2018 were EUR34,463 million, down 1.7% on a reported
basis and grew 2.5% at CER (up 0.6% at CER/CS).
- Sanofi Genzyme grew 30.8% (+14.2% at CER/CS) to EUR7,226
million.
- Vaccines sales increased 2.4% to EUR5,118 million while CHC sales
were up 3.0% to EUR4,660 million.
- DCV GBU sales declined 13.8% to EUR4,511 million.
- Emerging Markets sales were up 7.5%, supported by strong
performance in China (up 12.7%).
Sanofi delivers 2018 business EPS at the high end of its guidance
range
- Q4 2018 business EPS up 4.7% at CER to EUR1.10.
- Full-Year 2018 business EPS of EUR5.47 up 5.1% at CER and IFRS
EPS of EUR3.45 (down 48.5%).
- Board proposes dividend of EUR3.07, the 25th consecutive increase
in dividend.
Key achievements in sustaining innovation in R&D
- Isatuximab met primary endpoint of ICARIA phase 3 study in
Relapsed/Refractory Multiple Myeloma.
- BIVV001 demonstrated sustained high factor levels at once-weekly
dosing with data presented at ASH.
- FDA Priority Review granted for Dupixent(R) in adolescents with
moderate-to-severe atopic dermatitis.
- R&D strategy evolves towards prioritization of Specialty Care
and Vaccines, leveraging technology platforms and data science.
2019 financial outlook
- Sanofi expects 2019 business EPS to grow between 3% and 5% at
CER, barring unforeseen major adverse events. Applying average
January 2019 exchange rates, the positive currency impact on 2019
business EPS is estimated to be between 1% to 2%.
Sanofi Chief Executive Officer, Olivier Brandicourt, commented:
"In the fourth quarter, we continued the momentum of the previous
quarter and we delivered 5% full-year business EPS growth, at the
high end of our guidance. In 2018, we executed on important
launches including Dupixent(R), Libtayo(R) and Cablivi(R), as the
headwinds from our U.S. LoEs began to moderate. Additionally, the
acquisitions of Bioverativ and Ablynx provided the foundation to
build a leading Rare Blood Disorder franchise and to enhance our
biologic discovery capabilities. As we enter 2019, our focus
remains on delivering our business priorities and transforming
Sanofi to address the evolving business dynamics facing our
industry."
Q4 2018 Results: http://hugin.info/152918/R/2233891/878937.PDF
Investor Relations:
+33 1 53 77 45 45
E-mail: IR@sanofi.com
Media Relations:
+33 1 53 77 46 46
E-mail: MR@sanofi.com
Website: www.sanofi.com
Mobile app: SANOFI IR available on the App Store and Google
Play
Source: Sanofi
Copyright 2019 ACN Newswire . All rights reserved.
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024